Read more

June 29, 2021
1 min read
Save

Top psych stories of June: Cannabis and neurodevelopment, OCD increases dementia risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio Psychiatry has compiled a list of its five most-viewed stories in June.

A study on the association between OCD and increased risk for any dementia/Alzheimer’s disease, findings on altered neurodevelopment linked to adolescent cannabis use and research on the mental health burden of intern physicians were some of the most-read stories on Healio Psychiatry for the month.

OCD increases risk for any dementia, Alzheimer’s disease

Obsessive-compulsive disorder independently increased risk for subsequent dementia, including Alzheimer’s disease and vascular dementia, according to results of a nationwide longitudinal study published in Journal of Clinical Psychiatry. Read more.

Adolescent cannabis use may alter neurodevelopment

Cannabis use in middle to late adolescence may alter neurodevelopment, according to study results published in JAMA Psychiatry. Read more.

Work-related trauma exposure, PTSD common among intern physicians

Intern physicians commonly experienced work-related trauma exposure and PTSD, according to results of a cohort study published in JAMA Network Open. Read more.

Adults with depression, anxiety use more humor, sarcasm to cope with COVID-19 pandemic

Adults with depressive symptoms used more humor and sarcasm to cope with challenges brought on by the COVID-19 pandemic, according to survey results. Read more.

Oral adjunctive antidepressant treatment 'safe, well-tolerated, effective' in MDD

A researcher presented results of a phase 2, multicenter, randomized, double-blind, placebo-controlled three-arm trial that assessed outcomes related to esmethadone, called REL-1017 (Relmada Therapeutics Inc.), at the American Society of Clinical Psychopharmacology annual meeting. Read more.